{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:25:29Z","timestamp":1787952329794,"version":"build-2784847793"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/fpc.0b013e328329a60f","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T22:49:50Z","timestamp":1242946190000},"page":"373-382","source":"Crossref","is-referenced-by-count":68,"title":["Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents"],"prefix":"10.1097","volume":"19","author":[{"given":"Chadi A.","family":"Calarge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki L.","family":"Ellingrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Acion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Del D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Moline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Tansey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Schlechte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210212","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"R2-7-20210212","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","article-title":"Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"R3-7-20210212","article-title":"Risperidone-induced hyperprolactinemia is negatively associated with bone mineral density in youth, in National Institute of Mental Health (NIMH) New Clinical Drug Evaluation Unit (NCDEU)","author":"Calarge","year":"2008"},{"key":"R4-7-20210212","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R5-7-20210212","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","article-title":"Prolactin levels during long-term risperidone treatment in children and adolescents","volume":"64","author":"Findling","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R6-7-20210212","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s002139900364","article-title":"Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene","volume":"149","author":"Mihara","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R7-7-20210212","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajmg.1303","article-title":"Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol","volume":"105","author":"Mihara","year":"2001","journal-title":"Am J Med Genet"},{"key":"R8-7-20210212","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","article-title":"Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele","volume":"185","author":"Young","year":"2004","journal-title":"Br J Psychiatry"},{"key":"R9-7-20210212","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.mp.4000532","article-title":"Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers","volume":"4","author":"Jonsson","year":"1999","journal-title":"Mol Psychiatry"},{"key":"R10-7-20210212","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.mp.4000350","article-title":"The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers","volume":"3","author":"Pohjalainen","year":"1998","journal-title":"Mol Psychiatry"},{"key":"R11-7-20210212","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1021648128758","article-title":"Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics","volume":"28","author":"Ritchie","year":"2003","journal-title":"Neurochem Res"},{"key":"R12-7-20210212","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0920-9964(03)00220-2","article-title":"The 3\u2032 region of the DRD2 gene is involved in genetic susceptibility to schizophrenia","volume":"67","author":"Dubertret","year":"2004","journal-title":"Schizophr Res"},{"key":"R13-7-20210212","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01213011-200506000-00003","article-title":"The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects","volume":"15","author":"Laakso","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R14-7-20210212","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/hmg\/6.4.577","article-title":"A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia","volume":"6","author":"Arinami","year":"1997","journal-title":"Hum Mol Genet"},{"key":"R15-7-20210212","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/ddg055","article-title":"Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor","volume":"12","author":"Duan","year":"2003","journal-title":"Hum Mol Genet"},{"key":"R16-7-20210212","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.CHI.0000046843.56865.A5","article-title":"Assessment of safety in pediatric psychopharmacology","volume":"42","author":"Greenhill","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R17-7-20210212","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/104454601750143366","article-title":"Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters","volume":"11","author":"Moll","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R18-7-20210212","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R19-7-20210212","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization","volume":"52","author":"Colao","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R20-7-20210212","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.291.2.228","article-title":"Subclinical thyroid disease: scientific review and guidelines for diagnosis and management","volume":"291","author":"Surks","year":"2004","journal-title":"JAMA"},{"key":"R21-7-20210212","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/chi.0b013e3180686d7e","article-title":"Effects of stimulant medication on growth rates across 3 years in the MTA follow-up","volume":"46","author":"Swanson","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R22-7-20210212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004583-200001000-00014","article-title":"NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses","volume":"39","author":"Shaffer","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R23-7-20210212","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ Psychol Meas"},{"key":"R25-7-20210212","first-page":"189","article-title":"Pyrosequencing for SNP genotyping","volume":"212","author":"Ronaghi","year":"2003","journal-title":"Methods Mol Biol"},{"key":"R26-7-20210212","doi-asserted-by":"crossref","DOI":"10.1002\/0471249688","article-title":"Categorical data analysis","author":"Agresti","year":"2002"},{"key":"R27-7-20210212","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0024-3205(90)90131-A","article-title":"Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder","volume":"46","author":"Shaywitz","year":"1990","journal-title":"Life Sci"},{"key":"R28-7-20210212","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence","volume":"159","author":"Aman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R29-7-20210212","article-title":"Effect of atypical antipsychotics on prolactin levels and reproductive functioning in children and adolescents, in- American Academy of Child and Adolescent Psychiatry","author":"Correll","year":"2006"},{"key":"R30-7-20210212","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"R31-7-20210212","article-title":"Long-term safety and tolerability of aripiprazole in children (10\u201317) with mania, in- American Academy of Child and Adolescent Psychiatry","author":"Correll","year":"2007"},{"key":"R32-7-20210212","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R33-7-20210212","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2006.16.317","article-title":"The effect of long-term antipsychotic treatment on prolactin","volume":"16","author":"Staller","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R34-7-20210212","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JCP.0b013e31802e68d5","article-title":"Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism","volume":"27","author":"Troost","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R35-7-20210212","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1089\/cap.2005.15.893","article-title":"Elevated prolactin levels in male youths treated with risperidone and quetiapine","volume":"15","author":"Stevens","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R36-7-20210212","first-page":"565","article-title":"Pediatric Endocrinology","author":"Styne","year":"2002"},{"key":"R37-7-20210212","first-page":"455","article-title":"Pediatric Endocrinology","author":"Rosenfield","year":"2002"},{"key":"R38-7-20210212","first-page":"46","article-title":"Child and Adolescent Psychiatry, A Comprehensive Textbook","author":"Anderson","year":"2002"},{"key":"R39-7-20210212","first-page":"93","article-title":"Child and Adolescent Psychiatry, A Comprehensive Textbook","author":"Cummins","year":"2002"},{"key":"R40-7-20210212","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1203\/01.PDR.0000242848.45999.7b","article-title":"Iron deficiency in infancy predicts altered serum prolactin response 10 years later","volume":"60","author":"Felt","year":"2006","journal-title":"Pediatr Res"},{"key":"R41-7-20210212","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/FPC.0b013e3282f01aa3","article-title":"CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine","volume":"17","author":"Aklillu","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"R42-7-20210212","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.pnpbp.2008.05.006","article-title":"Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients","volume":"32","author":"Yasui-Furukori","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R43-7-20210212","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/archpsyc.1991.01810310066012","article-title":"Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism","volume":"48","author":"Noble","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"R44-7-20210212","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-199808000-00010","article-title":"Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients","volume":"18","author":"Nordstrom","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R45-7-20210212","first-page":"505","article-title":"The dopamine D2 receptor 5\u2032-flanking variant, \u2013141C Ins\/Del, is not associated with reduced dopamine D2 receptor density in vivo","volume":"9","author":"Pohjalainen","year":"1999","journal-title":"Pharmacogenetics"},{"key":"R46-7-20210212","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/sj.mp.4001561","article-title":"C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo","volume":"9","author":"Hirvonen","year":"2004","journal-title":"Mol Psychiatry"},{"key":"R47-7-20210212","doi-asserted-by":"crossref","first-page":"20552","DOI":"10.1073\/pnas.0707106104","article-title":"Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R48-7-20210212","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1176\/appi.ajp.163.3.529","article-title":"DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients","volume":"163","author":"Lencz","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R49-7-20210212","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R52-7-20210212","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.chi.0000235077.32661.61","article-title":"Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD","volume":"45","author":"Greenhill","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R53-7-20210212","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00004583-200302000-00008","article-title":"Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II","volume":"42","author":"Pappadopulos","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R54-7-20210212","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00004583-200302000-00007","article-title":"Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review","volume":"42","author":"Schur","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/01213011-200905000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T01:49:36Z","timestamp":1618364976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-200905000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e328329a60f","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}